Clinical Trials in Los Angeles

Showing 3441-3460 of 8,046 trials

NAC to Prevent Cisplatin-induced Hearing Loss

NCT02094625

Cisplatin is a key chemotherapy agent for the treatment of multiple childhood cancers but causes permanent hearing loss. This study investigates the drug N-acetylcysteine (NAC) to determine the dose necessary to protect hearing and also how well tolerated NAC is when combined with chemotherapy.

Neuroectodermal Tumors, PrimitiveLiver NeoplasmsOsteosarcoma+1 more

Children's Hospital Los Angeles52 participantsStarted Mar 2016

Los Angeles, California, United States

TERMINATEDPhase 3< 1 mile

Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease

NCT04152837

This is a Phase 3, open-label, repeat-dose study designed to assess liver safety, non-liver safety, and efficacy of lixivaptan in participants who previously experienced liver chemistry test abnormalities while treated with tolvaptan and were permanently discontinued from the drug for that reason. Up to 50 eligible participants will be enrolled and treated with lixivaptan for 52 weeks following titration to an optimal dose.

Polycystic Kidney Disease, AdultADPKD

Palladio Biosciences7 participantsStarted Sep 2020

Los Angeles, California, United States • Chicago, Illinois, United States • Rochester, Minnesota, United States +3 more locations

NAC to Prevent Cisplatin-induced Hearing Loss

Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease

Find Trials by Condition in Los Angeles

N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma

N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma

Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

Tavilermide Ophthalmic Solution for the Treatment of Dry Eye

A Study to Collect Participants Experience of Living With Adult Upper Limb (AUL) Spasticity and to Assess the Arm Activity Measure (ArmA)

A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer

A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America

Thrombosomes® in Bleeding Thrombocytopenic Patients

Topical NVN1000 for the Treatment of External Genital and Perianal Warts

Exercise Induced Plasma Volume Expansion Lowers Cardiovascular Strain

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures

Improving Cognition Via Exercise in Schizophrenia

ShockPulse-SE vs. Trilogy Trial: Comparing the Performance of Two Intracorporeal Lithotripters for Removal of Large Renal Calculi

Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)

A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)

Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis